OBJECTIVE: To describe the clinical course and outcome of 10 patients with Kawasaki disease (KD) treated with a calcineurin inhibitor after failing to respond to multiple therapies. STUDY DESIGN: Demographic and clinical data were prospectively collected using standardized case report forms. T-cell phenotypes were determined by flow cytometry, and KD risk alleles in ITPKC (rs28493229), CASP3 (rs72689236), and FCGR2A (rs1801274) were genotyped. RESULTS: Intravenous followed by oral therapy with cyclosporine (CSA) or oral tacrolimus was well tolerated and resulted in defervescence and resolution of inflammation in all 10 patients. There were no serious adverse events, and a standardized treatment protocol was developed based on our experiences with this patient population. Analysis of T-cell phenotype by flow cytometry in 2 subjects showed a decrease in circulating activated CD8(+) and CD4(+) T effector memory cells after treatment with CSA. However, suppression of regulatory T-cells was not seen, suggesting targeting of specific, proinflammatory T-cell compartments by CSA. CONCLUSION: Treatment of refractory KD with a calcineurin inhibitor appears to be a safe and effective approach that achieves rapid control of inflammation associated with clinical improvement.
OBJECTIVE: To describe the clinical course and outcome of 10 patients with Kawasaki disease (KD) treated with a calcineurin inhibitor after failing to respond to multiple therapies. STUDY DESIGN: Demographic and clinical data were prospectively collected using standardized case report forms. T-cell phenotypes were determined by flow cytometry, and KD risk alleles in ITPKC (rs28493229), CASP3 (rs72689236), and FCGR2A (rs1801274) were genotyped. RESULTS: Intravenous followed by oral therapy with cyclosporine (CSA) or oral tacrolimus was well tolerated and resulted in defervescence and resolution of inflammation in all 10 patients. There were no serious adverse events, and a standardized treatment protocol was developed based on our experiences with this patient population. Analysis of T-cell phenotype by flow cytometry in 2 subjects showed a decrease in circulating activated CD8(+) and CD4(+) T effector memory cells after treatment with CSA. However, suppression of regulatory T-cells was not seen, suggesting targeting of specific, proinflammatory T-cell compartments by CSA. CONCLUSION: Treatment of refractory KD with a calcineurin inhibitor appears to be a safe and effective approach that achieves rapid control of inflammation associated with clinical improvement.
Authors: Wenfang Wu; Ravi S Misra; Jennifer Q Russell; Richard A Flavell; Mercedes Rincón; Ralph C Budd Journal: J Biol Chem Date: 2006-02-02 Impact factor: 5.157
Authors: Uta Herden; Arno Kromminga; Christine Hagel; Jürgen Hartleb; Björn Nashan; Martina Sterneck; Lutz Fischer Journal: Ther Drug Monit Date: 2011-04 Impact factor: 3.681
Authors: Atilla Yilmaz; Anne Rowley; Danica J Schulte; Terence M Doherty; Nicolas W J Schröder; Michael C Fishbein; Mitra Kalelkar; Iwona Cicha; Katja Schubert; Werner G Daniel; Christoph D Garlichs; Moshe Arditi Journal: Exp Mol Pathol Date: 2007-02-01 Impact factor: 3.362
Authors: Adriana H Tremoulet; Brookie M Best; Sungchan Song; Susan Wang; Elena Corinaldesi; Julia R Eichenfield; Danielle D Martin; Jane W Newburger; Jane C Burns Journal: J Pediatr Date: 2008-03-04 Impact factor: 4.406
Authors: Taco W Kuijpers; Maarten Biezeveld; Annemiek Achterhuis; Irene Kuipers; Jan Lam; C E Hack; Anton E Becker; Allard C van der Wal Journal: Pediatrics Date: 2003-10 Impact factor: 7.124
Authors: Christine W Bruggeman; Sietse Q Nagelkerke; Wendy Lau; Cedric Manlhiot; Masja de Haas; Robin van Bruggen; Brian W McCrindle; Rae S M Yeung; Taco W Kuijpers Journal: Blood Adv Date: 2020-07-28